Literature DB >> 2897829

Chemotherapy of rhinovirus colds.

S J Sperber1, F G Hayden.   

Abstract

Mesh：

Substances：

Year:  1988        PMID： 2897829      PMCID： PMC172192          DOI： 10.1128/AAC.32.4.409

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  110 in total

1.  The failure of antihistaminic drugs to prevent or cure the common cold and undifferentiated respiratory diseases.

Authors:  A E FELLER; G F BADGER; R G HODGES; W S JORDAN; C H RAMMELKAMP; J H DINGLE
Journal:  N Engl J Med       Date:  1950-05-11       Impact factor: 91.245

2.  Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug.

Authors:  M P Fox; M J Otto; M A McKinlay
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

3.  The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating.

Authors:  T J Smith; M J Kremer; M Luo; G Vriend; E Arnold; G Kamer; M G Rossmann; M A McKinlay; G D Diana; M J Otto
Journal:  Science       Date:  1986-09-19       Impact factor: 47.728

4.  Intranasally administered atropine methonitrate treatment of experimental rhinovirus colds.

Authors:  M J Gaffey; J M Gwaltney; W E Dressler; J V Sorrentino; F G Hayden
Journal:  Am Rev Respir Dis       Date:  1987-01

5.  The spectrum of rhinovirus inhibitor by 2-(alpha-hydroxybenzyl)-benzimidazole and D-(-)-2-(alpha-hydroxybenzyl)-benzimidazole HC1.

Authors:  J M Gwaltney
Journal:  Proc Soc Exp Biol Med       Date:  1968-11

6.  Synergism between anti-rhinovirus antivirals: various human interferons and a number of synthetic compounds.

Authors:  A L Ahmad; D A Tyrrell
Journal:  Antiviral Res       Date:  1986-07       Impact factor: 5.970

7.  3,4-Dihydro-2-phenyl-2H-pyrano[2,3-b]pyridines with potent antirhinovirus activity.

Authors:  T M Bargar; J K Dulworth; M T Kenny; R Massad; J K Daniel; T Wilson; R N Sargent
Journal:  J Med Chem       Date:  1986-09       Impact factor: 7.446

8.  Antirhinovirus compound 44,081 R.P. inhibits virus uncoating.

Authors:  B Alarcon; A Zerial; C Dupiol; L Carrasco
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

9.  Intranasal interferon (rIFN-alpha A, Ro 22-8181) for contact prophylaxis against common cold: a randomized, double-blind and placebo-controlled field study.

Authors:  C Herzog; R Berger; M Fernex; K Friesecke; L Havas; M Just; U C Dubach
Journal:  Antiviral Res       Date:  1986-05       Impact factor: 5.970

10.  In vitro antiviral activity of the 6-substituted 2-(3',4'-dichlorophenoxy)-2H-pyrano[2,3-b]pyridines MDL 20,610, MDL 20,646, and MDL 20,957.

Authors:  M T Kenny; J K Dulworth; T M Bargar; H L Torney; M C Graham; A M Manelli
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191
View more
  22 in total

1.  Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes.

Authors:  D A Matthews; P S Dragovich; S E Webber; S A Fuhrman; A K Patick; L S Zalman; T F Hendrickson; R A Love; T J Prins; J T Marakovits; R Zhou; J Tikhe; C E Ford; J W Meador; R A Ferre; E L Brown; S L Binford; M A Brothers; D M DeLisle; S T Worland
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  Binding affinities of structurally related human rhinovirus capsid-binding compounds are related to their activities against human rhinovirus type 14.

Authors:  M P Fox; M A McKinlay; G D Diana; F J Dutko
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

Review 3.  Antihistamines and the common cold. A review and critique of the literature.

Authors:  D Luks; M R Anderson
Journal:  J Gen Intern Med       Date:  1996-04       Impact factor: 5.128

Review 4.  Problems and prospects of developing effective therapy for common cold viruses.

Authors:  S L Johnston
Journal:  Trends Microbiol       Date:  1997-02       Impact factor: 17.079

5.  Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds.

Authors:  S J Sperber; J V Sorrentino; D K Riker; F G Hayden
Journal:  Bull N Y Acad Med       Date:  1989-01

6.  Intranasal pirodavir (R77,975) treatment of rhinovirus colds.

Authors:  F G Hayden; G J Hipskind; D H Woerner; G F Eisen; M Janssens; P A Janssen; K Andries
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

7.  Pathway of rhinovirus disruption by soluble intercellular adhesion molecule 1 (ICAM-1): an intermediate in which ICAM-1 is bound and RNA is released.

Authors:  J M Casasnovas; T A Springer
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

8.  Prevention of human rhinovirus infection by multivalent fab molecules directed against ICAM-1.

Authors:  Catherine H Charles; Guang X Luo; Lori A Kohlstaedt; Ianessa G Morantte; Elliott Gorfain; Linguang Cao; Jimmy H Williams; Fang Fang
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

9.  In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug.

Authors:  M G Woods; G D Diana; M C Rogge; M J Otto; F J Dutko; M A McKinlay
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

10.  Efficient neutralization and disruption of rhinovirus by chimeric ICAM-1/immunoglobulin molecules.

Authors:  S Martin; J M Casasnovas; D E Staunton; T A Springer
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.